MetaCap

Ardelyx Inc. (ARDX)

NASDAQ: ARDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.99-0.07 (-2.29%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ARDX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$751.60M
EPS (TTM)
-$0.23
52-week range
2.80 – 8.40
Day range
2.95 – 3.08
Volume / Avg
6.20M / 4.46M
Beta
—

52-week range

$2.80$8.40

ARDX stock today

Shares of Ardelyx (ARDX) finished lower on Nov 20 at $2.99, a drop of 2.29% or $0.07 per share, versus the S&P 500's 3.70% decline. Shares are 64.4% below their 52-week high of $8.40, set on Jan 23, 2026 and 6.8% above the 52-week low of $2.80, near the bottom of the past year's range. ARDX is down 48.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.8%.

Ardelyx has posted a net loss over the last twelve months (EPS of -$0.23), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Ardelyx

Company profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Michael G. Raab
Headquarters
Waltham, MA
Employees
489
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Ardelyx generated $407.3 million in revenue, up 22.1% from fiscal 2024, its 7th consecutive year of revenue growth. Ardelyx reported a net loss of $61.6 million, compared with a loss of $39.1 million a year earlier. Gross margin was 90.3% (up from 84.8%) and operating margin -10.1%.

Ardelyx annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$407.32M$333.62M$124.46M$52.16M$10.10M
Growth+22.09%+168.06%+138.61%+416.57%+33.36%
Net income$-61.60M$-39.14M$-66.07M$-67.21M$-158.16M
EPS (diluted)$-0.26$-0.17$-0.30$-0.42$-1.52

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$12.50+318.06%

  • Strong buy 1
  • Buy 10
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $18.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$0.00 vs $-0.03
Surprise
+100.00%

ARDX news

All ARDX news

Ardelyx peers

Health Care sector
ARDX peer companies
CompanyPrice% ChgMarket capCompare
IVAInventiva S.A. American Depository Shares3.14-8.99%$750.78Mvs ARDX
RIGLRigel Pharmaceuticals Inc.40.09-2.67%$754.89Mvs ARDX
OBXObsidian Therapeutics Inc.12.00-1.23%$741.29Mvs ARDX
ORICOric Pharmaceuticals Inc.7.36-4.42%$764.94Mvs ARDX
COLLCollegium Pharmaceutical Inc.24.72-1.94%$768.18Mvs ARDX
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs ARDX
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs ARDX
VSTMVerastem Inc.6.33-7.73%$797.67Mvs ARDX

Indexes, lists and sector

Ardelyx stock FAQ

What is Ardelyx's stock price today?

ARDX last traded at $2.99 as of Nov 20, 4:00 PM EST, down 2.29% on the day. Prices are delayed at least 15 minutes.

Who is Ardelyx's CEO?

Mr. Michael G. Raab is the chief executive officer of Ardelyx Inc., which has about 489 employees.

What is the ARDX 52-week high?

The 52-week high for ARDX is $8.40 and the 52-week low is $2.80. The stock is currently 64.4% below its high.

Compare ARDX